Drug development program started based on CAP® Human Cell Line
New platform may provide solutions for many RA-patients around the world
Commenting on this unique co-operation, PharmaCell's CEO, Maurice Horsten, commented "Combining the strengths of our companies provides us with an excellent opportunity to build on PharmaCell's motto Humanizing Medicine® and to push this important project forward to the benefit of many patients around the world".
Cevec's CEO Dr Rainer Lichtenberger added: " CEVEC is excited about the strong scientific and commercial prospects of the Theraptech project. rhuAP will turn out to perfectly demonstrate the unique strengths of CEVEC's proprietary CAP® cell expression technology, in combination with the proven capabilities of our partners ".
On the scientific importance Alloksys' COO, Dr Ruud Brands commented: "rhuALP, based on the proposed mechanism of action in innate immune modulation, may enable the application in a wide array of disabling chronic inflammatory conditions, thereby eliminating the potentially adverse effects of currently marketed blockbuster products ".
About Alloksys Life Sciences BV - www.alloksys.eu
Alloksys Life Sciences BV, established in 2005 and located in Bunnik, The Netherlands is a biopharmaceutical company dedicated to the R&D of therapeutic proteins for the treatment of both acute and chronic inflammatory diseases. The lead phase II compound bIAP, an innate-immune system-modulating compound is developed for the indication: prevention of ischemia-reperfusion damage in invasive surgery. Chronic applications atherosclerosis, rheumatoid arthritis, Alzheimers and asthma are targeted. Alloksys established an integral research network comprising of several academic and biotech collaborations, both nationally and internationally. Partnerships with pharmaceutical companies for co-development of these indications are welcomed.
About PharmaCell - www.pharmacell.nl
PharmaCell provides contract services in the area of human cell & tissue banking & culturing as well as human cell line development and manufacturing of (bio) pharmaceuticals. Next to a GMP license, PharmaCell is the only commercial company in The Netherlands to hold an official license as Registered Tissue Establishment.
PharmaCell is also actively engaged in Research & Development work, both on behalf of some of its customers as well as in research consortia together with Universities, Academic Hospitals and other (bio)tech companies.
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T(TM) expression systems are ideal for manufacturing complex biopharmaceutical molecules. CEVEC is licensing out its human cell-based expression platform as well as the biological product candidates in internal development through partnerships with renowned pharmaceutical and biotech companies.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
Macht Alexa for Business HR-Manager überflüssig?
Bei rund 1,8 Millionen Nutzern ist Amazon Alexa bereits im privaten Umfeld als digitale Assistentin im Einsatz. Im Büro ist das noch Zukunftsmusik. Alexa for Business könnte das ändern – und möglicherweise auch die Personalabteilungen revolutionieren.Weiterlesen